Prevalence of depression and anxiety in patients with chronic obstructive pulmonary disease and their association with psychosocial outcomes: A cross-sectional study from Pakistan (original) (raw)
Related papers
International Journal of Advanced and Integrated Medical Sciences
Introduction Chronic disease like chronic obstructive pulmonary disease (COPD) is associated with various comorbidities. Anxiety and depression are among the common comorbidities and have significant impact on socioeconomic status of the person as well as the course of disease. In our study, we screened COPD patients attending the outpatient department (OPD) of pulmonary medicine for anxiety and depression, using different scales that include questionnaires. About 46.2 and 34.6% cases were found to have depression and anxiety respectively, among all COPD patients (n = 156). Incidence of anxiety and depression was directly proportional to severity of disease. Age, gender, locality, educational, marital, and socioeconomic statuses are some factors that play important roles in the development of these psychiatric comorbidities. Hence, mental assessment of COPD patients should be mandatory with every visit to the OPD. How to cite this article Jaiswal A, Kumar A, Rathi H, Sharma CS, Shar...
International Journal of Nursing Knowledge, 2015
The aim of this study was to develop the Arabic version of the Hospital Anxiety and Depression Scale (A-HADS) and test its psychometric proprieties for the assessment of anxiety and depression in patients with chronic obstructive pulmonary disease (COPD). METHOD: The A-HADS and Quality of Life Index Pulmonary version were completed by 67 Jordanian patients with COPD. RESULTS: Cronbach's alpha coefficient has been found to be 0.75 for the A-HADS anxiety subscale and 0.82 for the A-HADS depression subscale. A-HADS scores correlated significantly with the Quality of Life Index Pulmonary version and demonstrated construct validity. IMPLICATIONS: This preliminary validation study supports the A-HADS as a reliable and valid instrument for the assessment of anxiety and depression in Arabic speaking patients with COPD. Chronic obstructive pulmonary disease (COPD) is expected to be the third leading cause of death in middleincome countries by 2030 (Russell, Anzueto, & Weisman, 2011). The negative impact of COPD can be further complicated by the presence of psychological comorbidity in patients with COPD. It is well established that anxiety and depression are the most common psychological disorders of patients with COPD (
Asia-Pacific Psychiatry, 2009
Introduction: There is a high prevalence of psychiatric comorbidities in patients with Chronic Obstructive Pulmonary Disease (COPD). It has been reported that if left untreated, the psychiatric comobidities can lead to poorer quality of life. The present study was initiated to investigate the prevalence of major depressive disorder, generalized anxiety disorder and panic disorder in hospitalized COPD patients and their quality of life. Methods: The Patient Health Questionnaire (PHQ) of the Primary Care Evaluation of Mental Disorders (PRIME-MD) was administered to screen an opportunistic sample of COPD patients admitted to a general hospital for the abovementioned psychiatric disorders. The Medical Outcomes Study (MOS) 36-Item Short Form Health Survey (SF-36) was utilized to assess quality of life. Results: Fifty-one patients were analyzed. The prevalence of major depressive disorder in this sample on screening was 7.8% (95% CI 2.2-18.9) and that of anxiety disorders (generalized anxiety disorder and panic disorder) was 5.9% (95% CI 1.2-16.2). The quality of life of COPD patients with psychiatric comorbidities in the present study was severely impaired in seven of the eight domains measured by the SF-36. Discussion: Despite the small sample size of COPD patients, the prevalence of psychiatric comorbidities was not insignificant. The present study showed that the quality of life of hospitalized COPD patients with psychiatric illnesses was significantly lowered. Treatment of COPD should include addressing psychosocial issues.
BMC Psychiatry, 2017
Background: Anxiety and depression are usually under diagnosed among the patients with Chronic Obstructive Pulmonary Disease (COPD), which has a negative impact on patient quality of life through restriction of activities, loss of independence, and decreased social functioning. The purpose of this study was to describe the levels and characteristics of anxiety and depression in patients with COPD in Nepal as compared to the general population. Methods: A hospital-based observational comparative analytical study was conducted in the United Mission Hospital, Tansen and the Okhaldhunga Community Hospital, Okhaldhunga, Nepal from June 1st 2015 to April 15th 2016. A convenience sample of two groups of participants were recruited: patients with COPD (study group) and visitors to the facility (comparison group). Anxiety and depression were measured with the Beck Anxiety and Depression Inventory Scale. Results: A total of 198 individuals participated in the study; 93 with COPD and 105 from the general population. The mean age of the respondents was 58.24 ± 12.04 (40-82) years. The mean scores for anxiety and depression in COPD group were 23.76± 9.51 and 27.72± 9.37 respectively, while in comparison group, the mean score for anxiety was 8.01± 6.83 and depression was 11.60 ± 8.42. Both anxiety and depression scores were statistically significant between the groups with p value <0.001. Conclusions: Anxiety and depression were almost three times more common in COPD patients compared to the participants from the general population. Early assessment and multi-model treatment of anxiety and depression should be part of management in COPD.
PREVALENCE OF ANXIETY AND DEPRESSION IN STABLE PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE
National Journal of Medical Research, 2021
Introduction: To study the prevalence of anxiety and depression in stable COPD patients. Methodology: 100patients of stable COPD were assessed to look for the presence of anxiety and depression using beck anxiety inventory (BAI) and patient health questionnaire (PHQ-9). Patients already on treatment forpsychiatric illnesses were excluded from the study. Patients with total score above cut off value (BAI >7 ORPHQ-9 >4), were assessed in the psychiatry department. Quantitative data was compiled and statistical analysis was done. Results: Among study population 68% were males, 62% were in the age group of 60-80years, 83 % were ex smokers and 92 % of them were exposed to indoor air pollution (chullahs). It was found that 64 % of the study population had psychiatric morbidity out of which 42% had mixed anxiety and depressive symptoms. Psychiatric symptoms were more prevalent in female patients (97%, P value is0.003), and in patients who had more severe disease (P value is 0.04), 6 minute walk distance < 300 m (P value is 0.00001), percentage of desaturatoin> 3% after 6 M.W (P value is 0.0001) and Smoking Index >400.Smoking status and 6 minute walk distance were independently associated with the development of anxiety and depression with significant P values in stable COPD patients. Conclusion: Anxiety and depression are common psychiatric co-morbidities associated with COPD patients. Early diagnosis and proper management of COPD and timely evaluation for psychiatric illnesses is essential for the better outcomes in COPD patients.
Symptoms of anxiety and depression in patients with chronic obstructive pulmonary disease
Despite the prevalence and importance of anxiety and depressive symptoms in chronic obstructive pulmonary disease (COPD) patients, procedures for routine screening in therapeutic protocols are not commonly used. to assess the symptoms of anxiety and depression in COPD patients and to evaluate their relation to patients' demographic parameters and clinical characteristics. The research included 40 COPD patients, treated at the Institute of Lung Diseases and Tuberculosis, Clinical Centre Serbia in Belgrade, from November 2010 to February 2011. Study data were assessed by the questionnaire designed for the purposes of the present study together with Hamilton Anxiety Rating Scale (HARS) and Hamilton Depression Rating Scale (HDRS). Mean HARS score was 10.7 (SD=6.5) (22.5% subjects scored > or = 17) and mean HDRS score was 10.7 (SD=8.2) (20.0% subjects scored > or = 17). Depression was significantly higher in women (Z=-1.971: p=0.049). Lower value of forced expiratory volume in ...
Egyptian Journal of Chest Diseases and Tuberculosis, 2014
Background: COPD patients have to deal not only with the physical consequences of the disease, but they must also deal with the psychological consequences of COPD. Anxiety and depression are highly prevalent co morbidities in COPD. Objective: To assess the symptoms of depression and anxiety in COPD patients and to correlate between the severity of the anxiety and depression with the severity of the COPD. Subjects and methods: 80 COPD patients were assessed using SCID for establishing psychiatric diagnosis, Beck depression inventory for assessment of the severity of depressive symptoms, Hamilton anxiety scale for the severity of anxiety symptoms, Spirometry and arterial blood gases for assessing the severity of COPD; and were matched to 80 healthy controls. Results: The patient group showed higher statistically significant difference in the presence of psychiatric illness (55%, p = 0.001), anxiety level (22.5%, p = 0.06), depression level (42.5%, p = 0.0001), and substance abuse (15%, p = 0.035). Anxiety and depressive scores were significantly associated with the severity of COPD (p < 0.001). Anxiety score correlated with age (r = À0.267), and PaO 2 (r = 0.326). Depression score correlated with FEV1 (r = À0.262). Conclusion: This study proves the association between COPD and symptoms of anxiety and depression. The severity of anxiety and depression were correlated with the severity of COPD and the presence of lower PaO 2. Age, sex, duration of illness and previous ICU admission or mechanical ventilation did not correlate with depression or anxiety symptoms.
Anxiety and depression in chronic obstructive pulmonary disease: A new intervention and case report
Cognitive and Behavioral Practice, 2005
Anxzety and depmsston coexist frequently zn chronzc obstructwe pulmona~:y dzsease and compound the tmpact of the dzsease on quality of bfe and functzonal status Howev~ httle attentzon has been gwen to the development of treatment strategtes for thzs subset of patzents. The current artzcle describes the development of a new, mult~component cognztzve behavzoral treatment for reduczng anxzety and depresswn among patzents wtth respiratory dzsease (CBT-RADAR). Outcome data from a group of 5 patzents who partzczpated zn an ongoing clzn~cdl thai are revzewed to dlu~trate the strengths and hmztatlons of thzs mterventwn C HRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) is a serious and progressive medical illness with a profound impact on life function, economic burden, and mortality. Physical symptoms include shortness of breath, chest pain, cough, weakness, fatigue, poor exercise tolerance, nutritional abnormalities, and damage to the heart and brain. The disease affects 14 to 20 million people and is the fourth leading cause of death in the United States (Centers for Disease Control, 2003). Hospital readmission occurs frequently, and general rates of service use are high (Centers for Disease Control, 2005). Associated economic costs are estimated at $24 billion per year (Sullivan, Ramsey, & Lee, 2000). Quality of life and functional status are severely impaired as a result of both the physical symptoms and limitations of COPD and frequently coexistent psychological difficulties. Coexistent anxiety and depression are particularly common in COPD (Borson, Claypoole, & McDonald, 1998, Brenes, 2003). In many cases, the symptoms of COPD overlap with those of anxiety or depression (e.g., sleep disturbance, decreased energy, shortness of breath, and catastrophic thoughts about physical symptoms) and differential diagnosis is difficult. Nevertheless, anxiety and depressive diagnoses have been established via chnical interview in 16% to 34% of patients with COPD